Abstract 3736
Background
For decades, conventionally fractionated whole breast irradiation (CF-WBI) was used after breast conserving surgery (BCS). Pivotal phase 3 trials on hypofractionated-WBI (HF-WBI) showed its non-inferiority as compared to CF-WBI. However, younger patients (<60 years) are not currently worldwide treated with HF-WBI. The aim of this multi-center comparative study is to confirm the safety of HF-WBI in a real-life series of younger patients.
Methods
Between 2010 and 2016, a total of 786 patients aged less than 60 years old with early stage breast cancer were treated with postoperative WBI after BCS in three breast cancer centers: 340 underwent HF-WBI while 446 were treated with CF-WBI. Acute toxicity was evaluated at the end of WBI. Late toxicity was evaluated at 6, 12, 24, and 36 months.
Results
At univariate logistic analysis, hypofractionation showed a significant protective effect in terms of acute edema (p = 0.0001), acute wet desquamation (p = 0.009), chronic edema (p = 0.0001), chronic erythema/pigmentation (p = 0.0001), and breast fibrosis (p = 0.0002). At multivariate logistic analysis, hypofractionation was independent significant factor for acute edema (OR 0.09, 95% CI 0.02 to 0.48; p = 0.005), acute wet desquamation (OR 0.07, 95% CI 0.009 to 0.59; p = 0.014), and chronic edema (OR 0.18, 95% CI 0.04 to 0.75; p = 0.018). Significant association between individual characteristics and toxicity (grade 2 or more) are summarized in Table.Table:
215P
Toxicity | N | Protective factor | p-value | OR (95%CI) | Risk factor | p-value | OR (95%CI) |
---|---|---|---|---|---|---|---|
Acute edema | 43 | Hypofractionation Dmax/Prescribed dose° <107% | 0.0001 0.001 | 0.09 (0.03-0.30) 0.16 (0.06-0.46) | Chemotherapy | 0.002 | 2.63 (1.42-4.90) |
Chronic edema | 50 | Hypofractionation Dmax/Prescribed dose° <107% | 0.0001 0.003 | 0.20 (0.09-0.44) 0.31 (0.14-0.66) | EIC presence Boost dose >10 Gy Breast size >492 cc | 0.0001 0.032 0.003 | 3.0 (1.66-5.46) 9.02 (1.21-67.45) 2.67 (1.41-5.05) |
Acute erythema/ pigmentation | 163 | HER2 positive status Trastuzumab | 0.002 0.022 | 0.30 (0.14-0.63) 0.39 (0.18-0.87) | Smoking habits Boost dose >10 Gy Breast size >492 cc | 0.001 0.038 0.002 | 2.14 (1.37-3.32) 2.60 (1.06-6.41) 1.78 (1.24-2.54) |
Chronic erythema/ pigmentation | 110 | Hypofractionation Dmax/Prescribed dose° <107% | 0.0001 0.001 | 0.40 (0.25-0.63) 0.45 (0.28-0.73) | EIC presence Positive FSM Boost dose >10 Gy Breast size >492 cc | 0.0001 0.002 0.007 0.034 | 2.39 (1.54-3.71) 3.47 (1.56-7.71) 15.43 (2.08-114.3) 1.58 (1.04-2.41) |
Acute wet desquamation | 20 | Hypofractionation Dmax/Prescribed dose° <107% | 0.009 0.047 | 0.14 (0.03-0.61) 0.29 (0.08-0.99) | - | - | - |
Breast fibrosis | 117 | Hypofractionation Tumor grade Ki67 index Dmax/Prescribed dose° <107% | 0.0002 0.022 0.023 0.017 | 0.44 (0.29-0.68) 0.53 (0.31-0.92) 0.60 (0.38-0.93) 0.58 (0.37-0.91) | EIC presence Boost dose >10 Gy Breast size >492 cc | 0.0001 0.022 0.0001 | 3.03 (1.99-4.62) 6.76 (2.04-22.45) 2.84 (1.83-4.41) |
Conclusions
HF-WBI showed significantly improved toxicity outcomes in terms of both acute skin edema and wet desquamation, and chronic skin edema. HF-WBI after BCS should replace CF-WBI independently of age.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
740 - A real-world analysis of the treatment of advanced ovarian cancer with PARPIs
Presenter: Alejandra Martinez de Pinillos
Session: Poster Display session 2
Resources:
Abstract
5867 - Incidence of tumour BRCA1/2 variants in relapsed, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer
Presenter: Robert Morgan
Session: Poster Display session 2
Resources:
Abstract
2966 - Frequency of mutations in 21 hereditary breast and ovarian cancer susceptibility genes among 882 high-risk individuals
Presenter: Jihong Liu
Session: Poster Display session 2
Resources:
Abstract
1687 - BRCA testing of 1,284 Brazilian patients for hereditary breast and ovarian cancer in a routine diagnostic setting
Presenter: Fernanda Milanezi
Session: Poster Display session 2
Resources:
Abstract
3162 - A multi-center integrative study on cancer predisposition genes in Chinese patients with epithelial ovarian carcinoma
Presenter: Changbin Zhu
Session: Poster Display session 2
Resources:
Abstract
5993 - Incidental Early Occult Ovarian Cancer after Risk-Reducing Salpingo-Oophorectomy in BRCA1/2 Mutation Carriers followed in a Community Public Hospital
Presenter: Begona Grana Suarez
Session: Poster Display session 2
Resources:
Abstract
5334 - Response to chemotherapy in ovarian cancer (OC) patients with or without prior breast cancer (BC), stratified by BRCA mutation (BRCAm) status
Presenter: Angela George
Session: Poster Display session 2
Resources:
Abstract
4565 - Advanced ovarian cancer: is residual disease after debulking surgery affected by genetics factors involved in angiogenesis and immunity pathways?
Presenter: Michele Bartoletti
Session: Poster Display session 2
Resources:
Abstract
3251 - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study
Presenter: Fabrice Lecuru
Session: Poster Display session 2
Resources:
Abstract
3278 - Immune-Related Gene Expression Profiling after Neoadjuvant Chemotherapy (NACT) of Ovarian High-Grade Serous Carcinoma
Presenter: Luis Manso
Session: Poster Display session 2
Resources:
Abstract